Tarsus Pharmaceuticals, Inc. (TARS)
71.52
-1.29
(-1.77%)
USD |
NASDAQ |
Aug 25, 16:00
71.52
0.00 (0.00%)
After-Hours: 16:01
Tarsus Pharmaceuticals Enterprise Value : 2.790B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.790B |
| August 21, 2026 | 2.785B |
| August 20, 2026 | 2.732B |
| August 19, 2026 | 2.817B |
| August 18, 2026 | 2.713B |
| August 17, 2026 | 2.695B |
| August 14, 2026 | 2.633B |
| August 13, 2026 | 2.619B |
| August 12, 2026 | 2.669B |
| August 11, 2026 | 2.645B |
| August 10, 2026 | 2.571B |
| August 07, 2026 | 2.443B |
| August 06, 2026 | 2.466B |
| August 05, 2026 | 2.291B |
| August 04, 2026 | 2.283B |
| August 03, 2026 | 2.292B |
| July 31, 2026 | 2.194B |
| July 30, 2026 | 2.215B |
| July 29, 2026 | 2.171B |
| July 28, 2026 | 2.190B |
| July 27, 2026 | 2.240B |
| July 24, 2026 | 2.177B |
| July 23, 2026 | 2.174B |
| July 22, 2026 | 2.131B |
| July 21, 2026 | 2.117B |
| Date | Value |
|---|---|
| July 20, 2026 | 2.073B |
| July 17, 2026 | 2.229B |
| July 16, 2026 | 2.135B |
| July 15, 2026 | 2.127B |
| July 14, 2026 | 2.067B |
| July 13, 2026 | 2.205B |
| July 10, 2026 | 2.155B |
| July 09, 2026 | 2.414B |
| July 08, 2026 | 2.570B |
| July 07, 2026 | 2.692B |
| July 06, 2026 | 2.540B |
| July 02, 2026 | 2.471B |
| July 01, 2026 | 2.274B |
| June 30, 2026 | 2.362B |
| June 29, 2026 | 2.335B |
| June 26, 2026 | 2.407B |
| June 25, 2026 | 2.468B |
| June 24, 2026 | 2.587B |
| June 23, 2026 | 2.547B |
| June 22, 2026 | 2.434B |
| June 18, 2026 | 2.417B |
| June 17, 2026 | 2.391B |
| June 16, 2026 | 2.316B |
| June 15, 2026 | 2.361B |
| June 12, 2026 | 2.365B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Structure Therapeutics, Inc. | 2.154B |
| Alumis, Inc. | 2.494B |
| Veradermics, Inc. | 3.294B |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.55M |
| Revenue (Quarterly) | 173.91M |
| Total Expenses (Quarterly) | 192.46M |
| EPS Diluted (Quarterly) | -0.4275 |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -10.67% |
| Earnings Yield | -1.51% |
| Normalized Earnings Yield | -1.511 |